Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Michael Friedrich
  • Simon Jasinski-Bergner
  • Maria-Filothei Lazaridou
  • Karthikeyan Subbarayan
  • Chiara Massa
  • Sandy Tretbar
  • Anja Mueller
  • Diana Handke
  • Katharina Biehl
  • Jürgen Bukur
  • Marco Donia
  • Ofer Mandelboim
  • Barbara Seliger
Vis graf over relationer

Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy
Vol/bind68
Udgave nummer10
Sider (fra-til)1689-1700
Antal sider12
ISSN0340-7004
DOI
StatusUdgivet - okt. 2019

ID: 57730672